drugset / Trial / NCT07570823

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

NCT07570823

Phase 3 Not yet recruiting 101 enrolled Sinocelltech Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of SCTB35 in Combination With Gemcitabine and Oxaliplatin vs Rituximab in Combination With Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Timeline

Start
2026-05
Primary completion
2027-11
Completion
2029-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rituxumab Unknown Intravenous
Subject SCTB35 Unknown Subcutaneous
Background Gemcitabine Small molecule Intravenous
Background Oxaliplatin Small molecule Intravenous